KYAN Technologies
|
This article is a draft
It is still in development and may change significantly as it is expanded. If you like to contribute to this work, please reach out to the draft's author.
|
 | |
| Status | Active |
|---|---|
| Website | https://kyantechnologies.com/ |
| Vertical(s) | Medtech, Biotechnology |
| Latest Funding Round | Pre-Series A |
| Year founded | 2016 |
| Headquarters | Singapore |
| Technology Readiness Level | Deployment (TRL 7-8) |
KYAN Technologies is a Singapore-based startup that is developing a platform for precision medicine for both treatment and drug development.
Technology
KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy[1] across 20+ differnt cancer types.
Traction
List notable customers or partnerships here. Awards should not be listed here, but under "Accolades" instead
Accolades
List awards received by the startup here.
Funding
Describe the startup's funding history here. Include investors in the table below.
| Funding History | |
|---|---|
| Investor | Round |
| Altara Ventures | Pre-Series A |
| Seeds Capital | Pre-Series A |
| K3 Ventures | Pre-Series A |
Note: This list is community-maintained and may be incomplete or contain inaccuracies.
See also
- List any other pages directly relevant to KYAN Technologies
References
- ↑ "Optim.AI™ for Clinicians". KYAN Technologies. Retrieved 2025-12-20.